Login
$SGMT
$10.33 +$0.20 (1.97%) After hours

$SGMT SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G
12 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027

12 Nov 2026 10-Q
22 Oct 2026 8-K: Regulation FD Disclosure

Targeting Metabolic Dysfunction with Novel Therapeutics October 2026 Exhibit 99.1

07 Oct 2026 SCHEDULE 13G
01 Oct 2026 8-K: Entry into a Material Definitive Agreement

As representatives (the “Representatives”) of the several Underwriters

01 Oct 2026 424B5
30 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.1 Targeting Metabolic Dysfunction with Novel Therapeutics September 2026

30 Sep 2026 424B3
17 Aug 2026 Form 4: Kemble George, Director

Received 350,987 shares by exercise or conversion ($2.23M) · Sold 350,987 shares ($3.59M)

14 Aug 2026 144
14 Aug 2026 SCHEDULE 13G
13 Aug 2026 8-K: Other Events

On August 13, 2026, Sagimet Biosciences Inc. (the “Company”) announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application and issued a “Study May Proceed” letter for the Company’s Phase 3 clinical...

12 Aug 2026 Form 4: Kemble George, Director

Received 20,206 shares by exercise or conversion ($129K) · Sold 20,206 shares ($201K)

11 Aug 2026 144
11 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S.

11 Aug 2026 10-Q
30 Jul 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support